AstraZeneca shares drop over 5% after Alexion deal announcement

Monday, 14. December 2020 10:42

Shares of pharma giant AstraZeneca fell more than 5% on Monday trading after it was announced on Saturday that the company is buying rare-disease specialist Alexion Pharmaceuticals Inc. for $39 billion.

As part of the deal, Alexion shareholders will get $60 in cash and approximately $115 worth of equity per share, which based on an average of AstraZeneca's dollar-denominated American depositary shares price, is a premium of more than $50 per share.

At 10:39 am CET, shares were down by 5.37% to £7,722.00.

Related Links: AstraZeneca plcAlexion Pharmaceuticals Inc.
Breaking the News / TF